1 CBER Rare Diseases Program - Update 2011-2012 Nisha Jain, MD Chief, Clinical Review Branch DH/OBRR/CBER/FDA May 15, 2012 NORD Corporate Council.

Slides:

Advertisements

Similar presentations

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Regulatory Pathway for Platform Technologies

Center for Clinical Research - Clinical Trials Center (CTC) Clinical Research and Clinical Trials in Switzerland Jürg Lustenberger, PhD Dipl. Pharm. Med.

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Rare Diseases and FDASIA

Office of Orphan Products Development (OOPD) Gayatri R. Rao, M.D., J.D. Acting Director NORD Corporate Council May 15, 2012.

The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007.

Development of Guidance Documents Jennifer Scharpf, M. P. H

UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.

1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.

FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.

FDA Perspective Sally Loewke, M.D. Acting Division Director

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Special Topics in IND Regulation

1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.

1 FDA Regulation of Cellular, Tissue, and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies, FDA Phacilitate.

Cellular Tissue and Gene Therapies Research Site Visit Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies September 29,

Haffner Associates, LLC1 Orphan Drugs – 2011 What’s Happening? Women in BIO Marlene E. Haffner, MD, MPH Office 301.

Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.

Office of Combination Products: Current Initiatives

CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Mark Frohlich, MD, SVP and Chief Medical Officer September 25, 2008 Washington, DC 4 th Annual African American Prostate Cancer Disparity Summit.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.

OCTGT Overview Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies CTGTAC Meeting July 26, 2007.

National Heart, Lung, and Blood Institute Cancer Research Opportunities Liana Harvath, NHLBI U.S. Department of Health and Human Services National Institutes.

Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.

UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.

Summary: Biological Therapeutics for Rare Plasma Protein Disorders Workshop July 21, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER,

FDA’s Draft LDT Framework & Personalized Medicine Update

Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.

1 Safety of Cell Therapies Derived from Human Embryonic Stem Cells CTGTAC #45 April 10, 2008.

The Power of the Rare Disease Community… Diane Dorman Vice President, Public Policy National Organization for Rare Disorders (NORD) 1 st International.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,

FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.

FDA Office of Orphan Products Development

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

Large numbers of ill people seek care; EDs, clinics, and medical offices are crowded; there’s a surge on medical facilities; Delays in seeing a provider;

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

CDISC – 17/12/2012 Carine Javierre Nathalie SABIN.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Comments of International Society for Cellular Therapy (ISCT) to FDA Cellular, Tissue, & Gene Therapies Advisory Committee Elizabeth Read, MD March 30,

Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.

1 FDA Orphan Drug Designation 101 Gayatri R. Rao MD, JD Director Office of Orphan Products Development (OOPD) FDA October 12, 2012.

Transatlantic Administrative Simplification Workshop European Preparatory Roundtable Suzette Kox EGA Senior Director Scientific Affairs.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Efficacy Studies (PAES)

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014.

Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.

Peter Karlton 1 Regulatory Challenges A Diversity of Considerations Ethical Cultural Regulatory standards Strained resources Competing priorities Training.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.

Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.

Main topics Who are we at EMA and what is our regulatory experience in Parkinson’s disease (PD) Initiatives available at EMA to stimulate and support.

National Comparative Audit of the use of blood in Primary, Elective, Unilateral Total Hip Replacement This slideshow presents the main findings from the.

Stem Cell doubling is logarithmic

Biologic Medicines.

Supporting SME Eléonore Cornu M2 Areips Supporting SMEs.

The percentage of NASs approved by CDER

Introduction to Biosimilars

National Comparative Audit of the use of blood in Primary, Elective, Unilateral Total Hip Replacement This slideshow presents the main findings from the.

Timing for HCT Consultation

Suzanne M. Sensabaugh, MS, MBA

Quality and Process Improvement Program (QPIP)

Effectiveness Marlene Haffner, MD MPH Haffner Associates, LLC

Presentation transcript:

1 CBER Rare Diseases Program - Update Nisha Jain, MD Chief, Clinical Review Branch DH/OBRR/CBER/FDA May 15, 2012 NORD Corporate Council

2 Overview Products approved in Other updates Hopeful Future

3 Therapeutic areas Orphan Designated Products Of 70 biological products designated 28 are CBER products Total 14 grants awarded, 1 was for CBER product

4 Product Approvals

5 Approvals Sipuleucel-T: manufactured by Dendreon –Indication: For the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer Apligraf: manufactured by Organogenesis –Indication: treatment of surgically created gingival and alveolar mucosal surface defects Azficel-T: Manufactured by Fibrocell Technologies –Indication: for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults

6 Approvals (contd.) HEMACORD, HPC-C: manufactured by New York Blood Center –Indication: For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment

7 Approvals (contd.) Corifact: Factor XIII concentrate (Human) –Indication: prophylactic treatment of congenital Factor XIII (FXIII) deficiency Anascorp: Centruroides (Scorpion) Immune F(ab’)2 (Equine) –Indication: for treatment of clinical signs of scorpion envenomation

8 Guidances Biosimilars: 3 draft guidances published in February 2012 –Scientific Considerations in Demonstrating Biosimilarity to a Reference Product –Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product –Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of elopedandApproved/ApprovalApplications/TherapeuticBiologicApplicatio ns/Biosimilars/default.htm

9 Guidances (contd.) October 2011: Guidance for Industry Clinical Considerations for Therapeutic Cancer Vaccines December 2011: Guidance for Industry Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage gulatoryInformation/Guidances/default.htm

10 Collaboration with Foreign Regulators Parallel Scientific Advice with European Medicines Agency (EMA) –Increase the dialogue between the two agencies and sponsors from the beginning of the lifecycle of a new product –a deeper understanding of the bases of scientific advice –the opportunity to optimize product development and avoid unnecessary testing replication or unnecessary diverse testing methodologies ormation/ProceduresSOPPs/ucm htm

11 Future Directions PDUFA V : CBER Rare Disease liaison within the Office of Center Director Continue participation in CDER’s rare disease regulatory events: education, training, workshops etc. To work with CDER to expand the searchable database to include CBER products

12 Thank You!